Anebulo Pharmaceuticals Statistics
Share Statistics
Anebulo Pharmaceuticals has 25.93M shares outstanding. The number of shares has increased by 1.17% in one year.
| Shares Outstanding | 25.93M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.28M |
| Failed to Deliver (FTD) Shares | 81 |
| FTD / Avg. Volume | 0.86% |
Short Selling Information
The latest short interest is 10.76K, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 10.76K |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 1.94 |
Valuation Ratios
The PE ratio is -8.44 and the forward PE ratio is -2.54.
| PE Ratio | -8.44 |
| Forward PE | -2.54 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 18.15 |
| P/FCF Ratio | -8.55 |
| PEG Ratio | n/a |
Enterprise Valuation
Anebulo Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 13.46, with a Debt / Equity ratio of 0.
| Current Ratio | 13.46 |
| Quick Ratio | 13.46 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.15% and return on capital (ROIC) is -217.93%.
| Return on Equity (ROE) | -2.15% |
| Return on Assets (ROA) | -2.01% |
| Return on Capital (ROIC) | -217.93% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -4.10M |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -26.02% in the last 52 weeks. The beta is -1.01, so Anebulo Pharmaceuticals 's price volatility has been lower than the market average.
| Beta | -1.01 |
| 52-Week Price Change | -26.02% |
| 50-Day Moving Average | 1.69 |
| 200-Day Moving Average | 2.2 |
| Relative Strength Index (RSI) | 40.02 |
| Average Volume (20 Days) | 9.38K |
Income Statement
In the last 12 months, Anebulo Pharmaceuticals had revenue of $0 and earned -$8.20M in profits. Earnings per share was $-0.32.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -8.31M |
| Net Income | -8.20M |
| EBITDA | -8.05M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.32 |
Balance Sheet
The company has $3.09M in cash and $0 in debt, giving a net cash position of $3.09M.
| Cash & Cash Equivalents | 3.09M |
| Total Debt | 0 |
| Net Cash | 3.09M |
| Retained Earnings | -65.40M |
| Total Assets | 2.47M |
| Working Capital | 1.39M |
Cash Flow
In the last 12 months, operating cash flow was -$8.09M and capital expenditures $0, giving a free cash flow of -$8.09M.
| Operating Cash Flow | -8.09M |
| Capital Expenditures | 0 |
| Free Cash Flow | -8.09M |
| FCF Per Share | -0.31 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ANEB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -22.07% |
| FCF Yield | -21.59% |
Analyst Forecast
Currently there are no analyst rating for ANEB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -12.75 |
| Piotroski F-Score | 1 |